Drug news
EU CHMP recommends approval of Portrazza (necitumumab) for non-small cell lung cancer- Eli Lilly
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Portrazza (necitumumab), from Eli Lilly, intended for the treatment of epidermal growth factor receptor (EGFR)-expressing squamous non-small cell lung cancer.